MAP2K7 and melanoma: For 15 years, targeted therapy against BRAF(mutated in 50–60% of primary melanoma) or MEK protein has been developed, and some of these treatments have been commercialized, including BRAF inhibitors, such as vemurafenib (or PLX4032) and dabrafenib, and MEK inhibitors, such as cobimetinib, or trametinib (9).